Literature DB >> 11172097

Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure.

Tanja Henzler1, Abdallah Harmache1, Harald Herrmann1, Herbert Spring1, Marie Suzan2, Gilles Audoly2, Therese Panek1, Valerie Bosch1.   

Abstract

A variant human immunodeficiency virus type 1 (HIV-1) vif gene, vifA45-2, which encodes a protein lacking 19 amino acids at the C terminus but which is fully functional in supporting HIV replication in non-permissive cells has been described previously. By employing newly generated anti-VifA45 serum, further properties of VifA45 and its full-length counterpart, VifA45open, in comparison to Vif from HIV strain BH10 are reported in permissive HeLa and COS-7 cells. The results obtained using confocal microscopic localization studies and in vitro binding assays do not support a requirement for the direct interaction of HIV Gag with Vif. Furthermore and in contrast to previous conclusions, detergent solubility analyses do not demonstrate a role for the C terminus of Vif in mediating localization to the fraction containing cellular membrane proteins. Localization of Vif from HIV strain BH10 to perinuclear aggregates in a small fraction (about 10%) of transfected HeLa cells has been previously reported. The intermediate filament protein vimentin colocalizes to these structures. In contrast, VifA45 and VifA45open form perinuclear aggregates in nearly all transfected HeLa cells; vimentin as well as the cytoskeletal-bridging protein plectin, but not the microtubular protein tubulin, become relocalized to these structures. Interestingly, in COS-7 cells, all of the functional Vif proteins tested (Vif from strain BH10, VifA45 and VifA45open) predominantly localize in the cytoplasm but still induce dramatic aggregation of vimentin and plectin, i.e. in these cells the respective Vif proteins are influencing intermediate filament structure in the absence of colocalization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172097     DOI: 10.1099/0022-1317-82-3-561

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

Review 1.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

2.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.

Authors:  Nathan C Gaddis; Elena Chertova; Ann M Sheehy; Louis E Henderson; Michael H Malim
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA).

Authors:  Jessica L Reynolds; Supriya D Mahajan; Donald Sykes; Madhavan P N Nair
Journal:  Am J Infect Dis       Date:  2006

Review 5.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

6.  Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.

Authors:  Mohammad A Khan; Hirofumi Akari; Sandra Kao; Claudia Aberham; David Davis; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikunar Aalinkeel; Bindukumar Nair; Donald E Sykes; Anardi Agosto-Mujica; Chiu Bin Hsiao; Stanley A Schwartz
Journal:  J Clin Immunol       Date:  2009-06-20       Impact factor: 8.317

8.  Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.

Authors:  Sandra Kao; Hirofumi Akari; Mohammad A Khan; Markus Dettenhofer; Xiao-Fang Yu; Klaus Strebel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.

Authors:  Ana Clara Ribeiro; Alexandra Maia e Silva; Mariana Santa-Marta; Ana Pombo; José Moniz-Pereira; Joao Goncalves; Isabel Barahona
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.